Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Shah, J. Zonder, W. Bensinger, A. Cohen, J. Kaufman, A. Nooka, D. Weber, B. Hilder, Selena Rush, A. Ptaszynski, D. Walker, R. Orlowski (2013)
Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 StudyBlood, 122
M. Mateos, M. Cibeira, P. Richardson, F. Prósper, A. Oriol, J. Rubia, J. Lahuerta, R. García-Sanz, S. Extremera, S. Szyldergemajn, C. Corrado, H. Singer, C. Mitsiades, K. Anderson, J. Bladé, J. Miguel (2010)
Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple MyelomaClinical Cancer Research, 16
Shaji Kumar, B. Laplant, W. Chng, J. Zonder, N. Callander, R. Fonseca, B. Fruth, V. Roy, C. Erlichman, A. Stewart (2015)
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.Blood, 125 3
M. Weers, Y. Tai, M. Veer, J. Bakker, T. Vink, D. Jacobs, L. Oomen, M. Peipp, T. Valerius, J. Slootstra, T. Mutis, W. Bleeker, K. Anderson, H. Lokhorst, J. Winkel, P. Parren (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 186
J. San-Miguel, V. Hungria, S. Yoon, M. Beksaç, M. Dimopoulos, A. Elghandour, W. Jędrzejczak, A. Günther, T. Nakorn, N. Siritanaratkul, P. Corradini, S. Chuncharunee, Je-Jung Lee, R. Schlossman, T. Shelekhova, K. Yong, D. Tan, T. Numbenjapon, J. Cavenagh, J. Hou, R. LeBlanc, H. Nahi, L. Qiu, H. Salwender, S. Pulini, P. Moreau, K. Warzocha, D. White, J. Bladé, Wenming Chen, J. Rubia, P. Gimsing, S. Lonial, J. Kaufman, E. Ocio, Ljupco Veskovski, S. Sohn, Ming-Chung Wang, Jae Lee, H. Einsele, M. Sopala, C. Corrado, B. Bengoudifa, F. Binlich, P. Richardson (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.The Lancet. Oncology, 15 11
H. Lokhorst, J. Laubach, H. Nahi, T. Plesner, P. Gimsing, M. Hansson, M. Minnema, U. Lassen, J. Krejcik, T. Ahmadi, S. Lisby, L. Basse, N. Brun, P. Richardson (2014)
Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).Journal of Clinical Oncology, 32
C. Touzeau, Christelle Dousset, S. Gouill, D. Sampath, J. Leverson, A. Souers, S. Maïga, S. Maïga, S. Maïga, M. Béné, P. Moreau, C. Pellat-Deceunynck, C. Pellat-Deceunynck, C. Pellat-Deceunynck, M. Amiot, M. Amiot, M. Amiot (2013)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myelomaLeukemia, 28
P. Richardson, S. Jagannath, P. Moreau, A. Jakubowiak, M. Raab, T. Facon, R. Vij, D. White, D. Reece, L. Benboubker, J. Zonder, L. Tsao, K. Anderson, E. Bleickardt, A. Singhal, S. Lonial (2014)
Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaBlood, 124
G. Srkalović, M. Hussein, A. Hoering, J. Zonder, L. Popplewell, Harsha Trivedi, Sandra Mazzoni, R. Sexton, R. Orlowski, B. Barlogie (2014)
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434Cancer Medicine, 3
S. Lonial (2013)
"A fortuitous combination of circumstances".Blood, 122 16
J. Shah, J. Zonder, A. Cohen, W. Bensinger, J. Kaufman, R. Orlowski, R. Harvey, M. Abidi, S. Thomas, D. Walker, B. Hilder, A. Ptaszynski, S. Lonial (2012)
The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 StudyBlood, 120
Xiaohua Xin, T. Abrams, P. Hollenbach, K. Rendahl, Yan Tang, Y. Oei, M. Embry, D. Swinarski, E. Garrett, N. Pryer, S. Trudel, B. Jallal, D. Mendel, C. Heise (2006)
CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in MiceClinical Cancer Research, 12
P. Richardson, S. Jagannath, P. Moreau, A. Jakubowiak, Marc-Steffen Raab, T. Facon, R. Vij, D. White, D. Reece, L. Benboubker, J. Zonder, L. Tsao, Kenneth Anderson, E. Bleickardt, A. Singhal, S. Lonial (2015)
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.The Lancet. Haematology, 2 12
M. Andrulis, N. Lehners, D. Capper, R. Penzel, C. Heining, J. Huellein, T. Zenz, A. Deimling, P. Schirmacher, A. Ho, H. Goldschmidt, K. Neben, M. Raab (2013)
Targeting the BRAF V600E mutation in multiple myeloma.Cancer discovery, 3 8
K. Anderson (2012)
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 4
G. An, Hua Jiang, C. Acharya, M. Zhong, T. Cai, Guang Yang, Zhili Song, J. Theilhaber, F. Adrián, Y. Tai, K. Anderson (2014)
SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple MyelomaBlood, 124
M. Santra, F. Zhan, E. Tian, B. Barlogie, J. Shaughnessy (2003)
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.Blood, 101 6
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, David Smith, David McDermott, J. Powderly, Richard Carvajal, J. Sosman, M. Atkins, P. Leming, D. Spigel, S. Antonia, L. Horn, Charles Drake, D. Pardoll, Lieping Chen, W. Sharfman, Robert Anders, J. Taube, T. McMiller, Haiying Xu, A. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. Kollia, A. Gupta, J. Wigginton, M. Sznol (2012)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.The New England journal of medicine, 366 26
A. Cohen, C. Hofmeister, M. Nikhil, S. Jagannath, Y. Efebera, G. Spitzer, R. Zerbib, P. André, Shawna Oxier, M. Caligiuri (2013)
A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple MyelomaBlood, 122
Shaji Kumar, W. Bensinger, T. Zimmerman, C. Reeder, J. Berenson, D. Berg, A. Hui, N. Gupta, A. Bacco, Jiang Yu, Y. Shou, R. Niesvizky (2014)
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Blood, 124 7
S. Russell, M. Federspiel, K. Peng, Caili Tong, D. Dingli, W. Morice, V. Lowe, Michael O'Connor, R. Kyle, N. Leung, F. Buadi, S. Rajkumar, M. Gertz, M. Lacy, A. Dispenzieri (2014)
Remission of disseminated cancer after systemic oncolytic virotherapy.Mayo Clinic proceedings, 89 7
A. Yordanova, D. Hose, K. Neben, M. Witzens‐Harig, I. Gütgemann, M. Raab, T. Moehler, H. Goldschmidt, I. Schmidt-Wolf (2013)
Sorafenib in patients with refractory or recurrent multiple myelomaHematological Oncology, 31
Suzanne Trudel, Scott Ely, Yildiz Farooqi, M. Affer, D. Robbiani, M. Chesi, P. Bergsagel (2004)
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.Blood, 103 9
J. Sharman, J. Chmielecki, D. Morosini, G. Palmer, J. Ross, P. Stephens, J. Stafl, V. Miller, S. Ali (2014)
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.Clinical lymphoma, myeloma & leukemia, 14 5
Janelle Sharkey, T. Khong, A. Spencer (2007)
PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.Blood, 109 4
E. Alici (2010)
IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers.Current opinion in molecular therapeutics, 12 6
R. Berger, R. Rotem‐Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni, A. Nagler (2008)
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic MalignanciesClinical Cancer Research, 14
R. Vij, C. Huff, W. Bensinger, D. Siegel, S. Jagannath, J. Berdeja, N. Lendvai, D. Lebovic, L. Anderson, C. Costello, K. Stockerl-Goldstein, J. Laubach, L. Elias, F. Clow, M. Fardis, T. Graef, Elizabeth Bilotti, P. Richardson (2014)
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 ResultsBlood, 124
A. Spencer, S. Yoon, S. Harrison, S. Morris, Deborah Smith, R. Brigandi, J. Gauvin, Rakesh Kumar, J. Opalinska, Christine Chen (2014)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.Blood, 124 14
D. Chauhan, Ajita Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. Palladino, K. Anderson (2007)
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.Blood, 111 3
This minireview covers novel drugs and treatment concepts being evaluated in early studies for therapy of patients with multiple myeloma (MM). Panobinostat, a histone deacetylase inhibitor, showed limited improvement in progression-free survival, thus raising doubt whether these substances will provide clinical meaningful benefits in MM. Some of the new proteasome inhibitors beyond carfilzomib offer the benefit of oral administration and reduced neurotoxicity. Monoclonal antibodies with antimyeloma or antistroma cell activity raise expectations for improved treatment outcome when combined with conventional chemotherapy. A series of new inhibitors of signal pathways important for proliferation and progression in MM presently are scrutinized for their clinical usefulness. Among these, inhibitors of the mitogen activated protein kinase (MAPK), epidermal growth factor receptor (EGFR), protein kinase B (AKT), and B-cell receptor pathway as well as drugs inhibiting the spindle protein, Bcl-2, and cyclin-dependent kinases show promise for becoming important antimyeloma dugs. Checkpoint inhibitors have shown significant activity in some solid tumors and are now tested in MM as well. Measles viruses bind via CD46 to myeloma cells, self-amplify at sites of tumor growth, and induce cell death in myeloma but not in normal cells, thus offering a completely new treatment strategy. However, before introduction of these interesting approaches into the clinic, confirmation of their clinical efficacy is needed.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jan 30, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.